FDA Clears Casgevy Gene Therapy for Sickle Cell Patients as Young as 2

The Food and Drug Administration on July 1 granted a supplemental approval that pushes the age floor for Casgevy, the CRISPR-based gene therapy for sickle cell disease and transfusion-dependent beta thalassemia, down from 12 years to 2 years old. The decision, detailed in an FDA press announcement reviewed by ETL Newswire, makes Casgevy the first gene therapy cleared for young children with either condition in the United States.

For families who've spent years watching a toddler cycle in and out of the hospital for pain crises, that's not a small shift. Sickle cell disease causes red blood cells to become rigid and misshapen, blocking blood flow and oxygen delivery to vital organs. Recurrent vaso-occlusive crises, the unpredictable episodes of severe pain that are a hallmark of the disease, frequently require hospitalization. The younger the patient, the longer cumulative organ damage has to accumulate before any curative option was on the table.

Casgevy works by editing a patient's own blood stem cells using CRISPR/Cas9 technology to increase fetal hemoglobin production, which reduces red blood cell sickling in sickle cell disease and can eliminate transfusion dependence in beta thalassemia patients. According to the Vertex Pharmaceuticals investor release, the FDA reviewed the supplemental application in 53 days after filing, and the therapy carries Orphan Drug, Regenerative Medicine Advanced Therapy, and Fast Track designations.

The population math matters here. According to the Vertex announcement, roughly 5,500 additional children in the U.S. are now eligible, on top of the adolescent and adult pool covered by the original 2023 authorization. That's a meaningful expansion on paper. Whether those children can actually access the therapy is a different question entirely.

Casgevy is an autologous therapy, meaning it uses each patient's own stem cells, which have to be collected, edited at a manufacturing facility, and then reinfused after the patient undergoes myeloablative conditioning, essentially a chemotherapy regimen intense enough to clear the bone marrow. That process requires a specialized transplant center with cellular therapy infrastructure. As noted in coverage from Healthcare Readers, transplant centers across the U.S. are already managing strained capacity from rising demand for CAR-T and other cellular therapies. Adding a younger, smaller patient population doesn't simplify those logistics.

Cost also hasn't changed. Casgevy carries a list price in the range of $2 million or more per treatment, and pediatric hematologists and health system formulary committees will now face pressure to define criteria for toddler-age candidates, a population whose long-term outcomes data from clinical trials is still maturing.

Haydar Frangoul, MD, Medical Director of HCA Healthcare's Sarah Cannon Transplant and Cellular Therapy Program at TriStar Centennial Children's Hospital, and a clinical investigator in the Casgevy development program, said in the epocrates clinical summary that earlier access would allow clinicians and families to consider treatment "before years of cumulative damage from these life-shortening diseases take hold." That's the right clinical frame. The question pediatric hematologists will be wrestling with now is how to weigh the real but still-emerging safety and durability data in the under-12 group against the known trajectory of untreated disease in a 2-year-old.

Regulatory review for the same label expansion is underway in the United Kingdom and Saudi Arabia, according to the Vertex announcement.

Sources cited:
- FDA Press Announcement, July 1, 2026 (https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-young-children-sickle-cell-disease)
- Vertex Pharmaceuticals Investor Release, July 1, 2026 (https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-us-fda-approval-expanded-use-casgevyr-treatment)
- HCPLive, July 1, 2026 (https://www.hcplive.com/view/fda-expands-exa-cel-casgevy-gene-therapy-approval-2-years-scd-b-thalassemia)
- Epocrates Clinical Summary, July 2026 (https://www.epocrates.com/online/article/fda-expands-casgevy-label-to-younger-children-with-sickle-cell-disease)
- Healthcare Readers Roundup, July 4, 2026 (https://healthcarereaders.com/news/healthcare-news-27th-june-to-4th-july-2026)